These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 1115110)

  • 21. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
    Shumin X; Johannisson E; Landgren BM; Diczfalusy E
    Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of prostaglandin F2 alpha infusion on corpus luteum function.
    Jones GS; Wentz AG
    Am J Obstet Gynecol; 1972 Oct; 114(3):393-404. PubMed ID: 4637460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma levels of progesterone during the luteal phase in normal women treated with synthetic oestrogens (RS 2874, F 6103 and ethinyloestradiol).
    Johansson ED; Gemzell C
    Acta Endocrinol (Copenh); 1971 Nov; 68(3):551-60. PubMed ID: 5171371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 17alpha-ethinyl-19-nortestosterone (ENT) on corpus luteum function.
    Lehmann F; Just-Nastansky I; Czygan PJ; Bettendorf G
    Eur J Obstet Gynecol Reprod Biol; 1976; 6(4):219-22. PubMed ID: 987942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women.
    Bergquist C; Nillius SJ; Wide L
    Contraception; 1980 Sep; 22(3):287-93. PubMed ID: 7002443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of postovulatory estradiol benzoate administration on women's ovarian function.
    Oriol-Bosch A; Cortés J
    Fertil Steril; 1975 May; 26(5):405-12. PubMed ID: 1126465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum follicle-stimulating and luteinizing hormone and progesterone in single and multiple gestations following induction of ovulation.
    Fogel M; Rubin BL; Ossowski R
    Am J Obstet Gynecol; 1972 Mar; 112(5):629-39. PubMed ID: 5059593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
    Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
    J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiovulatory activity of synthetic corticoids.
    Cunningham GR; Caperton EM; Goldzieher JW
    J Clin Endocrinol Metab; 1975 Feb; 40(2):265-7. PubMed ID: 1117979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Blockade of LH and FSH peaks by low doses of exogenous progesterone in the human female (author's transl)].
    Netter A; Gorins A; Thomas K; Cohen M; Joubinaux J
    Ann Endocrinol (Paris); 1973; 34(4):430-5. PubMed ID: 4779738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
    Bouchard P; Wolf JP; Hajri S
    Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The induction of premature luteolysis in normal women--follicular phase luteinizing hormone secretion and corpus luteum function in the subsequent cycle.
    Soules MR; Bremner WJ; Dahl KD; Rivier JE; Vale WW; Clifton DK
    Am J Obstet Gynecol; 1991 Apr; 164(4):989-94; discussion 994-6. PubMed ID: 2014851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days.
    Siriwongse T; Snidvongs W; Tantayaporn P; Leepipatpaiboon S
    Contraception; 1982 Nov; 26(5):487-93. PubMed ID: 6218964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
    Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
    Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mid-cycle contraception with LHRH in women.
    Maia H; Barbosa IC; Maia H; Coutinho EM
    Reproduccion; 1981; 5(4):251-60. PubMed ID: 7033017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal profile in IUD users.
    Souka AR; Rahman H; Osman M; Mohei Y; Rizk M
    Contracept Deliv Syst; 1981 Oct; 2(4):303-10. PubMed ID: 12336991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of progesterone receptor blockade in the luteal phase of normal fertile women.
    Li TC; Dockery P; Thomas P; Rogers AW; Lenton EA; Cooke ID
    Fertil Steril; 1988 Nov; 50(5):732-42. PubMed ID: 3181485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to intermittent RU486 in women.
    Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
    Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.